A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge ... specialist Sidekick and pharma group Eli Lilly. The two companies say the ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

Investors in Eli Lilly (Symbol: LLY) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company chose Kenosha County for its latest – and one of its largest ...

BT: With anti-obesity drugs gaining global traction, how is Eli Lilly adapting its global success strategies to suit the Indian market? VG: Obesity is a growing health challenge in India ...